Cardiovascular Clinical Trials Market To Reach $21.6 Billion By 2033

Cardiovascular Clinical Trials Market Growth & Trends

The global cardiovascular clinical trials market size is estimated to reach USD 21.6 billion by 2033, registering a CAGR of 7.7% from 2026 to 2033, according to a new report by Grand View Research, Inc. The market's growth is majorly due to the increasing prevalence of cardiovascular diseases such as heart failure, stroke, and coronary artery diseases. Furthermore, the persistent advancements in medical research, including personalized medicine and genomics, fuel the need for clinical trials to investigate novel strategies and therapies. In addition, technological innovations in clinical research, such as the adoption of virtual clinical trials and remote monitoring of clinical trial patients, facilitate more cost-effective and efficient clinical trial management, thus supporting the growth of the market.

The market is fragmented, with several players having similar technological and processing capabilities. Several contract research organizations are penetrating the space of cardiovascular clinical trials. Moreover, these companies are focusing on innovating cardiovascular treatment therapies with experimentation over novel compounds. These players focus on partnerships and collaborations with bio-pharmaceutical companies to enhance their market presence. For instance, in August 2023, Dr. Vince Clinical Research (DVCR); a clinical research organization, announced a strategic alliance with Clario for delivering cardiac assessments in clinical trials.

Furthermore, the globalization of clinical trials is another significant factor supporting the market's growth. For instance, in May 2022, according to the clinical trials arena, the involvement of Western commercial companies in trials run in China has grown gradually from around 100 trials per year in 2010 to around 350 trials in 2021. Hence, this is one of the primary factors supporting the market growth during the forecast period.

The COVID-19 pandemic negatively impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving cardiovascular indications. However, the market recovered by adopting novel trial methods such as virtual and decentralized clinical trials.

 Request a free sample copy or view report summary: Cardiovascular Clinical Trials Market Report

Cardiovascular Clinical Trials Market Report Highlights

• Based on phase, the phase III segment held the largest market share of 55.5% in 2025, driven by a surge in late-stage studies validating the safety and efficacy of novel therapies aimed at large patient populations.

• Based on study design, the interventional trials segment accounted for the largest share in 2025, driven by increased demand for assessing new drugs, biologics, medical devices, and surgical methods for cardiovascular diseases.

• Based on indication, the ischemic heart disease segment held the largest revenue share in 2025, driven by global prevalence and significant mortality rates.

• Based of service, the laboratory services segment accounted for the largest share in 2025, attributed to underscoring their vital role in sample testing, biomarker analysis, diagnostic evaluations, and data validation throughout clinical studies. 

• By sponsor, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share in 2025, driven by leveraging investments in the development of innovative therapies.

• North America cardiovascular clinical trials market accounting for a revenue share 50.7% of the global market in 2025, attributed to growing R&D investments and the presence of established pharmaceutical and biotechnology companies.

Cardiovascular Clinical Trials Market Segmentation

Grand View Research has segmented the global cardiovascular clinical trials market based on phase, study design, indication, indication by study design, service, sponsor, and region:

Cardiovascular Clinical Trials Phase Outlook (Revenue, USD Million, 2021 - 2033)

• Phase I

• Phase II

• Phase III

• Phase IV

Cardiovascular Clinical Trials Study Design Outlook (Revenue, USD Million, 2021 - 2033)

• Interventional Trials

• Observational Trials

• Expanded Access Trials

Cardiovascular Clinical Trials Indication Outlook (Revenue, USD Million, 2021 - 2033)

• Valvular Heart Disease

• Peripheral Artery Disease

• Ischemic Heart Disease

• Pulmonary Arterial Hypertension

• Stroke

• Cardiac Arrhythmias

• Heart Failure

• Other Indications

Cardiovascular Clinical Trials Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)

• Valvular Heart Disease

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

• Peripheral Artery Disease

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

• Ischemic Heart Disease

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

• Pulmonary Arterial Hypertension

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

• Stroke

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

• Cardiac Arrhythmias

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

• Heart Failure

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

• Other Indications

  • Interventional Trials

  • Observational Trials

  • Expanded Access Trials

Cardiovascular Clinical Trials Service Outlook (Revenue, USD Million, 2021 - 2033)

• Protocol Designing

• Site Identification

• Patient Recruitment

• Laboratory Services

• Analytical Testing Services

• Clinical Trial Data Management Services

• Others

Cardiovascular Clinical Trials Sponsor Outlook (Revenue, USD Million, 2021 - 2033)

• Pharmaceutical & Biopharmaceutical Companies

• Medical Device Companies

• Others

Cardiovascular Clinical Trials Regional Outlook (Revenue, USD Million, 2021 - 2033) 

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

  • Columbia

• Middle East and Africa (MEA)

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List of Key Players in the Cardiovascular Clinical Trials Market

• IQVIA Inc.

• ICON plc

• SGS SA

• Eli Lilly and Company

• PPD Inc.

• Syneos Health

• Caidya

• Worldwide Clinical Trials

• Veeda Clinical Research

• Parexel International (MA) Corporation

• Medpace Holdings, Inc.

• Charles River Laboratories

• MAC Research

• Sofpromed

• Laboratory Drug Development

• AstraZeneca

• Novartis

• Pfizer

• Bristol Myers Squibb

• Johnson & Johnson